AI
HIMSS24
Prashant Natarajan, VP of strategy and products at H20.ai, says he is looking forward to discussing generative AI and the patient experience as well as strategies and success stories with fellow HIMSS24 attendees.
Dr. Peter Bonis, chief medical officer at Wolters Kluwer Health, describes the company's AI-enabled software to detect illicit diversion of controlled and non-controlled substances in patient care and the use of AI in its wider portfolio.
It is consolidating its contact centre functionalities across sites in Australia and Europe.
HIMSS24
Brenna Loufek, SaMD regulatory affairs manager at Mayo Clinic, discusses her HIMSS24 session on bringing AI-enabled digital health tools built under research into the clinical setting and what she hopes the audience will gain from the discussion.
Dr. Melek Somai, chief technology and product officer at Froedtert & Medical College of Wisconsin Health Network, discusses how Froedtert and Inception Health use genAI, including helping patients with scheduling and navigating healthcare.
Dr. Melek Somai, chief technology and product officer at Froedtert & Medical College of Wisconsin Health Network, relays how genAI is impacting various sectors of healthcare and how harnessing the tech will extend human discovery in medicine.
Alongside generative AI, the large database has been foundational to the development of its latest AI-powered drug discovery system.
The company will offer a customizable version of its Marketplace Search Technology to health plans supporting Medicare beneficiaries.
Also, AIRS Medical has recently signed a strategic partnership to accelerate its expansion in Australia and New Zealand.
Also, Qure.ai has obtained breakthrough device designation for its tuberculosis AI.